{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:30:16Z","timestamp":1786667416314,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18\u201375 years with overweight (BMI 24-28\u2009kg\/m\u00b2 plus \u2265 1 comorbidity) or obesity (BMI\u2009\u2265\u200928\u2009kg\/m\u00b2) were randomly assigned (3:1) to receive once-daily VCT220 (80\u2009mg, 120\u2009mg, or 160\u2009mg with slow or fast titration) or placebo for 16 weeks, alongside lifestyle counselling. The primary endpoint was the percentage change in body weight from baseline to week 16. Two-hundred and fifty participants were randomized (61 to placebo, 189 to VCT220). At week 16, mean body weight decreased by \u22125.75% (80\u2009mg) to \u22129.73% (160 mg-FT) versus \u22121.61% with placebo (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The proportion achieving \u22655% weight loss ranged from 55.4% (80\u2009mg) to 90.3% (160 mg-ST) with VCT220 versus 13.1% with placebo. VCT220 also improved HbA1c, fasting insulin, and blood pressure. Adverse events were mainly mild-to-moderate gastrointestinal events, most common during titration, and rarely led to discontinuation. VCT220, a once-daily oral nonpeptide GLP-1RA, produced rapid and clinically meaningful weight loss with metabolic benefits over 16 weeks, showing a tolerability profile consistent with the class. These findings support further global phase III evaluation to further verify the efficacy and safety of VCT220 as well as potential cardiometabolic benefits.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02859-2","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:01:54Z","timestamp":1786665714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Linong","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2859_CR1","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton, S. et al. Obesity in adults: a clinical practice guideline. CMAJ. 192, E875\u2013E891 (2020).","journal-title":"CMAJ."},{"key":"2859_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","volume":"9","author":"X-F Pan","year":"2021","unstructured":"Pan, X.-F., Wang, L. & Pan, A. Epidemiology and determinants of obesity in China. Lancet Diab. Endocrinol. 9, 373\u2013392 (2021).","journal-title":"Lancet Diab. Endocrinol."},{"key":"2859_CR3","first-page":"90","volume":"16","author":"National Health Commission of the People\u2019s Republic of China","year":"2025","unstructured":"National Health Commission of the People\u2019s Republic of China Department of Medical Administration. Chinese diagnosis and treatment guideline for obesity (2024 edition) (in Chinese). Peking. Union Med. J. 16, 90\u2013108 (2025).","journal-title":"Peking. Union Med. J."},{"key":"2859_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong, H. J. et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diab. Care 48, 292\u2013300 (2025).","journal-title":"Diab. Care"},{"key":"2859_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","volume":"67","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial. Diabetologia 67, 1783\u20131799 (2024).","journal-title":"Diabetologia"},{"key":"2859_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705\u2013719 (2023).","journal-title":"Lancet"},{"key":"2859_CR7","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2022).","journal-title":"Mol. Metab."},{"key":"2859_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"MA Nauck","year":"2016","unstructured":"Nauck, M. A. et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diab. Care 39, 231\u2013241 (2016).","journal-title":"Diab. Care"},{"key":"2859_CR9","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1111\/dom.13764","volume":"21","author":"JP Frias","year":"2019","unstructured":"Frias, J. P. et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diab. Obes. Metab. 21, 2048\u20132057 (2019).","journal-title":"Diab. Obes. Metab."},{"key":"2859_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA 332, 551\u2013560 (2024).","journal-title":"JAMA"},{"key":"2859_CR11","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton, S. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796\u20131806 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2859_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu, Y. et al. Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly East Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diab. Endocrinol. 12, 184\u2013195 (2024).","journal-title":"Lancet Diab. Endocrinol."},{"key":"2859_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup, A. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 36, 843\u2013854 (2012).","journal-title":"Int. J. Obes."},{"key":"2859_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/dom.12175","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I. & Mannucci, E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diab. Obes. Metab. 16, 38\u201347 (2014).","journal-title":"Diab. Obes. Metab."},{"key":"2859_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias, J. P. et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet 402, 472\u2013483 (2023).","journal-title":"Lancet"},{"key":"2859_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2859_CR17","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD). Diab. Care 41, 2669\u20132701 (2018).","journal-title":"Diab. Care"},{"key":"2859_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","volume":"102","author":"KD Hall","year":"2018","unstructured":"Hall, K. D. & Kahan, S. Maintenance of lost weight and long-term management of obesity. Med. Clin. North Am. 102, 183\u2013197 (2018).","journal-title":"Med. Clin. North Am."},{"key":"2859_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","volume":"45","author":"J Trujillo","year":"2020","unstructured":"Trujillo, J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J. Clin. Pharm. Ther. 45, 43\u201360 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"2859_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 11, 202\u2013230 (2014).","journal-title":"Rev. Diabet. Stud."},{"key":"2859_CR21","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/JCI97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker, D. J., Habener, J. F. & Holst, J. J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Invest. 127, 4217\u20134227 (2017).","journal-title":"J. Clin. Invest."},{"key":"2859_CR22","doi-asserted-by":"publisher","first-page":"eadp5765","DOI":"10.1126\/scitranslmed.adp5765","volume":"16","author":"KW Sloop","year":"2024","unstructured":"Sloop, K. W. et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci. Transl. Med. 16, eadp5765 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2859_CR23","unstructured":"Bo, L., Yu, H., Ben, L., Juan, H. & Bo, L. Mechanism of CX11\u2019s QD vs. Danuglipron\u2019s BID via AI-PBPK Modeling. Obesity. 33, (abstr. 323) (2025)."},{"key":"2859_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1056\/NEJMp2513633","volume":"394","author":"AB Troxel","year":"2026","unstructured":"Troxel, A. B. et al. Statistics in medicine - what\u2019s in an estimand? N. Engl. J. Med. 394, 6\u20139 (2026).","journal-title":"N. Engl. J. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02859-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02859-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:01:55Z","timestamp":1786665715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02859-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2859"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02859-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LNJ is the leading PI of this study, which is funded by Chengdu Vincentage Pharma Co., Ltd. BL is a full-time employee of and stockholder at Chengdu Vincentage Pharma Co., Ltd. ML is a full-time employee of Chengdu Vincentage. Others have nothing to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"325"}}